Ken Griffin Cel Sci Corp Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cel Sci Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 27,100 shares of CVM stock, worth $18,970. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,100

Previous 16,600 63.25%

Holding current value

$18,970

Previous $19,000 47.37%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.05 - $1.5 $9,716 - $13,881	-9,254 Reduced 25.37%	27,220 $28,000
Q2 2024 Aug 14, 2024	BUY	$1.11 - $1.85 $1,032 - $1,720	930 Added 2.62%	36,474 $42,000
Q1 2024 May 15, 2024	SELL	$1.63 - $3.08 $17,884 - $33,793	-10,972 Reduced 23.59%	35,544 $67,000
Q4 2023 Feb 14, 2024	BUY	$1.07 - $3.07 $2,847 - $8,169	2,661 Added 6.07%	46,516 $126,000
Q3 2023 Nov 14, 2023	BUY	$1.17 - $2.86 $21,157 - $51,717	18,083 Added 70.17%	43,855 $54,000
Q2 2023 Aug 14, 2023	BUY	$2.11 - $2.83 $54,378 - $72,934	25,772 New	25,772 $62,000
Q4 2022 Feb 14, 2023	BUY	$1.99 - $3.52 $187,601 - $331,837	94,272 Added 291.49%	126,613 $297,000
Q3 2022 Nov 14, 2022	SELL	$3.09 - $5.23 $209,693 - $354,918	-67,862 Reduced 67.72%	32,341 $100,000
Q2 2022 Aug 15, 2022	SELL	$2.58 - $4.99 $67 - $129	-26 Reduced 0.03%	100,203 $451,000
Q1 2022 May 16, 2022	SELL	$3.93 - $7.7 $794,767 - $1.56 Million	-202,231 Reduced 66.86%	100,229 $394,000
Q4 2021 Feb 14, 2022	BUY	$7.1 - $12.82 $944,747 - $1.71 Million	133,063 Added 78.55%	302,460 $2.15 Million
Q3 2021 Nov 15, 2021	BUY	$7.64 - $12.49 $697,088 - $1.14 Million	91,242 Added 116.74%	169,397 $1.86 Million
Q1 2021 May 17, 2021	BUY	$12.0 - $27.64 $388,668 - $895,231	32,389 Added 70.77%	78,155 $1.19 Million
Q2 2020 Aug 14, 2020	SELL	$9.75 - $17.6 $306,998 - $554,171	-31,487 Reduced 40.76%	45,766 $683,000
Q2 2019 Aug 14, 2019	BUY	$3.77 - $8.67 $218,151 - $501,689	57,865 Added 298.46%	77,253 $647,000
Q1 2019 May 15, 2019	SELL	$2.58 - $3.54 $163,192 - $223,915	-63,253 Reduced 76.54%	19,388 $0
Q2 2018 Aug 10, 2018	BUY	$0.92 - $3.5 $76,029 - $289,243	82,641 New	82,641 $0
Q1 2018 May 11, 2018	SELL	$1.38 - $2.33 $27,003 - $45,593	-19,568 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$1.63 - $2.0 $31,895 - $39,136	19,568	19,568 $37,000

Others Institutions Holding CVM

# of Institutions

Shares Held

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $30.4M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account